Group 1 - Tongyu Communication's subsidiary Zhonghong Tongyu plans to introduce Wuhan Wuchuang Institute as an investor through a capital increase of 10 million yuan, raising its registered capital from 200 million yuan to 210 million yuan, and reducing Tongyu's shareholding from 90% to 85.7143% [1] - Sanli Pharmaceutical signed a technology transfer contract with Hainan University to acquire the patent rights for the HXW2324 compound, aimed at developing new Alzheimer's disease treatments, for a total price of 200 million yuan [2] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Shenzhen Dahuang Robot Technology to enhance collaboration in the development and manufacturing of general humanoid robot dexterous hands [3] Group 2 - Dook Culture announced a potential change in control, leading to a temporary suspension of its stock trading starting December 22, 2025, to ensure fair information disclosure [4] - Nanya New Materials plans to raise no more than 900 million yuan through a private placement to fund AI-based high-frequency copper-clad laminate projects and supplement working capital [5] - Hexing Packaging's major shareholder reduced their stake by 700,000 shares during a period of stock price volatility, consistent with previously disclosed plans [6] Group 3 - Yongding Co. plans to increase capital and introduce external investors, including Cambridge Technology, with a total cash increase of 55 million yuan, resulting in a decrease in its shareholding in Dingxin Optoelectronics [7] - ChaoSheng Electronics intends to invest 1 billion yuan in a high-performance HDI printed circuit board expansion and upgrade project, expecting to add an annual production capacity of 240,000 square meters [8] - Lingyi ZhiZao signed an agreement to acquire 35% of the shares of Limin Da for 875 million yuan, gaining control over 52.78% of the voting rights in the company [10] Group 4 - Sanhua Intelligent Control forecasts a net profit of 3.874 billion to 4.649 billion yuan for 2025, representing a year-on-year growth of 25% to 50% [11] - Aolian Electronics announced a potential change in control due to the planned transfer of shares by its major shareholder, leading to a temporary stock suspension starting December 22, 2025 [12]

证券日报网讯12月22日晚间，南亚新材发布公告称，公司将于2026年1月7日召开2026年第一次临时股东 会。 ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - Nanya New Materials (688519.SH) plans to issue shares to specific investors, raising up to 900 million yuan, with net proceeds intended for AI-based high-frequency high-speed copper-clad laminate R&D and working capital supplementation [1] Group 1 - The company aims to raise a total of no more than 900 million yuan, including the principal amount [1] - The net proceeds after deducting issuance costs will be invested in R&D and industrialization projects related to AI computing power [1] - Additional funds will be used to supplement the company's working capital [1]

Group 1 - The company, Nanya New Materials (688519.SH), announced a plan to issue shares to specific investors, aiming to raise a total of no more than 900 million yuan (including the principal) [1] - The net proceeds from the fundraising, after deducting issuance costs, are intended for investment in the research and industrialization of AI-powered high-frequency high-speed copper-clad laminates, as well as to supplement working capital [1]

南亚新材料科技股份有限公司 2025年度向特定对象发行A股股票方案的论证分析报告 公司代码：688519 证券简称：南亚新材 南亚新材料科技股份有限公司 （上海市嘉定区南翔镇昌翔路158号） 2025年度向特定对象发行A股股票 方案的论证分析报告 二〇二五年十二月 1 2 南亚新材料科技股份有限公司 2025年度向特定对象发行A股股票方案的论证分析报告 南亚新材料科技股份有限公司（以下简称"南亚新材"或"公司"）是上海证券 交易所科创板上市的公司。为满足公司业务发展的资金需求，增强公司资本实力，提 升盈利能力，根据《公司法》《证券法》《南亚新材料股份有限公司章程》和中国证监 会颁布的《上市公司证券发行注册管理办法》（以下简称《管理办法》）等有关法律、 法规和规范性文件的规定，公司拟向特定对象发行股票，募集资金不超过 90,000.00 万元。 本报告中如无特别说明，相关用语具有与《南亚新材料科技股份有限公司 2025 年度向特定对象发行 A 股股票预案》中的释义相同的含义。 一、本次向特定对象发行股票的背景和目的 （一）本次发行的背景 1、国家产业政策支持我国电子专用材料产业快速发展 信息技术产业是关系国民经 ...

Group 1 - The company Nanya New Materials (688519) disclosed a plan on December 22 to issue A-shares to specific investors, aiming to raise no more than 900 million yuan [1] - The funds raised will be used for the research and industrialization of high-end, high-frequency, high-speed copper-clad laminates based on AI computing power, as well as to supplement working capital [1]

Group 1 - Company Nanya New Materials (南亚新材) announced the approval of a stock issuance to specific targets, with a maximum of 35 participants, aiming to raise up to 900 million yuan [1] - The number of shares to be issued will not exceed approximately 70.43 million shares, which is 30% of the company's total shares before the issuance [1] - The issuance price will be no less than 80% of the average trading price of the company's A-shares over the 20 trading days prior to the pricing date [1] Group 2 - As of the report, the market capitalization of Nanya New Materials is 15.4 billion yuan [2] - The company's revenue composition for the year 2024 is projected to be 98.17% from electronic specialty materials and 1.83% from other businesses [1]

格隆汇12月22日丨南亚新材(688519.SH)公布2025年度向特定对象发行A股股票预案，本次向特定对象发 行股票募集资金总额不超过9亿元（含本数），扣除发行费用后的净额拟投资于以下项目：基于AI算力 的高阶高频高速覆铜板研发及产业化项目、补充流动资金。 ...

南亚新材料科技股份有限公司 2025 年度向特定对象发行 A 股股票预案 南亚新材料科技股份有限公司 2025 年度向特定对象发行 A 股股票预案 公司声明 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不 存在虚假记载、误导性陈述或重大遗漏。 公司代码：688519 证券简称：南亚新材 南亚新材料科技股份有限公司 （上海市嘉定区南翔镇昌翔路158号） 2025年度向特定对象发行A股股票预案 二〇二五年十二月 1 2 南亚新材料科技股份有限公司 2025 年度向特定对象发行 A 股股票预案 特别提示 1、公司本次向特定对象发行股票相关事项已经公司第三届董事会第二十五 次会议审议通过，尚需公司股东会审议通过、上海证券交易所审核通过并经中国 证监会作出予以注册的批复后方可实施。 2、本次向特定对象发行股票的发行对象为不超过 35 名（含 35 名）符合法 律法规规定的特定对象，包括证券投资基金管理公司、证券公司、信托公司、财 务公司、资产管理公司、保险机构投资者、合格境外机构投资者、其他境内法人 投资者、自然人或其他合格投资者。证券投资基金管理公司、证券公司、合格境 外机构投资者、人民币合格境外 ...